Online Inquiry & Support

USA: 1-631-626-9181   Fax: 1-631-614-7828
Europe: 44-207-097-1828
Email: info@creative-bioarray.com

SEARCH

tissue samples, tissue arrays, cells, microorganisms, probes and services for your research.

  

SEARCH

Contact Support
Interested in our Products & Services?
Need detailed information?
Can't find the products of interest?
Need it customized?
Click Here & Contact Support
Contact Us
    • USA
      45-1 Ramsey Road, Shirley, NY 11967, USA
      Tel: 1-631-626-9181
      Fax: 1-631-614-7828
      Email: info@creative-bioarray.com
      Europe
      Tel: 44-207-097-1828
      Email: info@creative-bioarray.com
Ordering Information
    • Payment methods we support:
      ✭ Invoice / Purchase Order
      ✭ Credit card

Patient-derived Tumor Xenograft (PDX) Model

Bookmark and Share

Patient-derived tumor xenograft (PDX) model

The primary goal of cancer research is to better understand tumorigenesis and cancer progression. However, the complex nature of tumors has posed a substantial challenge to unlocking cancer’s secrets. The contribution of newly developed therapeutics to improved patient survival has been limited, despite significant time, money, and effort has been expended over the last half century.

Monocellular layers of tumors cultivated in vitro and mouse xenografts derived from those cells have been the standard toolkit for cancer biologists for decades. Unfortunately, continuous passage and culture of cells in vitro allows the least differentiated cells to thrive, resulting in distinct and irreversible losses of important biologic properties introduced by tumor resident cell populations, such as supporting non-tumor stroma, hematopoietic cells and other tumor microenvironmental factors. Based on this situation, mouse xenografts of human tumor cell lines have had poor predictive power in the translation of cancer therapeutics into clinical settings.

To better preserve the genomic integrity and tumor heterogeneity observed in patients, patient-derived xenograft (PDX) models were generated using freshly resected patient tumors immediately transplanted into immunocompromised murine hosts without an intermediate in vitro culture step.

Creative Bioarray is well equipped with advanced research platforms and exquisite technical team for establishing diverse and reliable PDX models, either subcutaneous tumor xenografts or orthotopic human tumor xenograft models, which targets the following categories, but is not limited to:

  • Breast Cancer

As the leading type of cancer in women, breast cancer is cancer that develops from breast tissue, which accounts for 25% of all cases worldwidely.

  • Lung Cancer

Lung cancer is a malignant lung tumor with uncontrolled cell proliferation in tissues of the lung, which contains two main types: small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC).

  • Gastric Cancer

Gastric cancer is cancer developing from the lining of the stomach, which may spread from the stomach to other parts of the body, particularly the liver, lungs, bones, lining of the abdomen and lymph nodes.

  • Colorectal Cancer

Colorectal cancer is developed from the colon or rectum, which have strong capacity of invasion to other parts of the body.

  • Pancreatic Cancer

Pancreatic cancer is a kind of cancer initiated from the pancreas, which bears a strong capacity of invasion to other parts of the body.

Creative Bioarray PDX models advantages

  • High engraftment rate
  • Increased clinical relevance compared to CDX models
  • Reconstitution of relevant tumor microenvironment
  • Site specific study for anti-tumor treatment
  • Assess of tumor-stromal interactions

Workflow

Patient-derived tumor xenograft (PDX) model

Applications

  • Tumorigenicity
  • Multi-drug resistance
  • Therapeutic effect evaluation

Creative Bioarray is dedicated to establish the most competitive service platforms for Oncology research. Our scientific staff can assist you and provide compelling service chain for PDX models investigation, aiming to create effective pre-clinical investigation by reasonable resource utilization as well as exquisite biomedical attainments. Our all-around service from animal model construction, pathophysiological examination to data processing will qualify your test as well as simplify your whole project.

Study examples

Patient-derived tumor xenograft (PDX) model

Fig.1. Predictive biomarker development strategy in PDTX models

Quotation and ordering

If you have any special needs in establishment or application of PDX models, please contact us at info@creative-bioarray.com or 1-631-626-9181 for this special service. Let us know what you need and we will accommodate you. We look forward to working with you in the future.

References

1. Williams, S.A.; et al. Patient-derived xenografts, the cancer stem cell paradigm, and cancer pathobiology in the 21st century. Laboratory Investigation. 2013, 93: 970–982.
2. Despina, S.; Hannon, G.J. Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res. 2013, 73(17): 5315-5319.
3. Tentler, J.J.; et al. Patient-derived tumour xenografts as models for oncology drug development. Nature Reviews Clinical Oncology. 2012, 19: 338-350.

Technical Support & Price Inquiry

Please input "bioarray" as verification code.

Contact Us
USA
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-626-9181
Fax: 1-631-614-7828
Email: info@creative-bioarray.com

Europe
Tel: 44-207-097-1828
Email: info@creative-bioarray.com